UroGen (URGN) 2025 Earnings: What Investors Should Know
As UroGen prepares to report 2025 results, investors weigh Jelmyto sales, pipeline progress, and balance-sheet health...
Explore which Low Cost Dividend ETF to invest in right now. We compare costs, yields, and diversification to help you decide efficiently.
27,336 articlesAs UroGen prepares to report 2025 results, investors weigh Jelmyto sales, pipeline progress, and balance-sheet health...
The first half of 2026 delivered a sharp downturn for Salesforce as AI-driven disruption and market rotation shook th...
Investors are watching a potential shift at HubSpot as AI features expand across its platform. This guide breaks down...
As AI spending hits record levels, Chamath Palihapitiya argues the real test is whether buyers of AI can deliver dura...
The SEC submitted interpretive guidance to OIRA to clarify how federal securities laws could apply to crypto assets. ...
Trump unveils a plan to monetize passage through the Strait of Hormuz, triggering market moves and raising questions ...
An almost 12% jump in lantheus holdings stock popped last month left investors asking what lit the fuse. This article...
Robinhood Just Launched Blockchain marks a bold shift for everyday investors. This guide breaks down what it means, h...
Rivian unveils the R2 with a sub-$45k price target and near-term shipments, while Lucid battles cash burn and no 2026...
As an upcoming investor update looms, you may wonder if you should microsoft stock be before the news. This guide bre...
Oracle has reframed the AI shift as a disruption to traditional SaaS growth. This article explains why that view matt...
Lucid stock has moved sharply lower, fueling debates about whether it’s a risky fall or a potential bargain. This gui...